| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Research Abstract |
Establishment of a method to assess CDDP resistance before treatment would make it possible to avoid unnecessary administration in cases when no effect was expected. We conducted a comprehensive, protein-level analysis of human head and neck cancer cell lines using a ProteinChip System with cell lines that had sensitivity to CDDP, acquired resistance, and natural resistance. We found two peaks and may therefore be effective markers for predicting CDDP effectiveness. Extracted proteins were labeled with iTRAQ and analyzed to identify resistance. Protein expression was confirmed by western blotting and analysis using siRNA. Seven proteins with specific resistance to CDDP, including alfa-enolase. Functional analysis for alfa-enolase by siRNA showed that CDDP sensitivity significantly was increased in naturally resistant cell line. Such proteins could be used as biomarkers for anticancer agent resistance and as targets of cancer therapy.
|
